Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 2
1970 4
1971 1
1972 3
1973 3
1974 3
1975 4
1976 2
1977 3
1978 1
1979 1
1980 2
1981 1
1982 4
1983 4
1984 4
1985 5
1986 2
1987 3
1988 3
1989 1
1990 5
1991 5
1992 2
1993 7
1994 8
1995 5
1996 7
1997 5
1998 7
1999 11
2000 10
2001 12
2002 6
2003 6
2004 10
2005 10
2006 12
2007 16
2008 16
2009 18
2010 27
2011 31
2012 31
2013 41
2014 50
2015 65
2016 60
2017 69
2018 58
2019 62
2020 53
2021 60
2022 67
2023 64
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

891 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Brain stem astrocytic neoplasm"
Page 1
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Schaff LR, Mellinghoff IK. Schaff LR, et al. JAMA. 2023 Feb 21;329(7):574-587. doi: 10.1001/jama.2023.0023. JAMA. 2023. PMID: 36809318 Review.
Treatment of primary CNS lymphoma includes high-dose methotrexate-containing regimens, followed by consolidation therapy with myeloablative chemotherapy and autologous stem cell rescue, nonmyeloablative chemotherapy regimens, or whole brain radiation. CONCLUSIONS AN …
Treatment of primary CNS lymphoma includes high-dose methotrexate-containing regimens, followed by consolidation therapy with myeloablative …
Molecular targeted therapy of glioblastoma.
Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Le Rhun E, et al. Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11. Cancer Treat Rev. 2019. PMID: 31541850 Free article. Review.
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. ...There is increasing interest in targeting not only the tumor cells, but also the microenvironment, including blood vessels, the monocyte/macrophage/microglia c …
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. ...There is increasing …
Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma.
Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Biserova K, et al. Cells. 2021 Mar 11;10(3):621. doi: 10.3390/cells10030621. Cells. 2021. PMID: 33799798 Free PMC article. Review.
The aim of the current paper is to provide an overview of current knowledge on the role of cancer stem cells in the pathogenesis and treatment resistance of glioblastoma. The six regulatory mechanisms of glioma stem cells (GSCs)-tumor microenvironment, niche concept …
The aim of the current paper is to provide an overview of current knowledge on the role of cancer stem cells in the pathogenesis and …
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. Majzner RG, et al. Nature. 2022 Mar;603(7903):934-941. doi: 10.1038/s41586-022-04489-4. Epub 2022 Feb 7. Nature. 2022. PMID: 35130560 Free PMC article. Clinical Trial.
We have previously shown that the disialoganglioside GD2 is highly expressed on H3K27M-mutated glioma cells and have demonstrated promising preclinical efficacy of GD2-directed chimeric antigen receptor (CAR) T cells(2), providing the rationale for a first-in-human phase I cli …
We have previously shown that the disialoganglioside GD2 is highly expressed on H3K27M-mutated glioma cells and have demonstrated promising …
Glioblastoma multiforme: Pathogenesis and treatment.
Alifieris C, Trafalis DT. Alifieris C, et al. Pharmacol Ther. 2015 Aug;152:63-82. doi: 10.1016/j.pharmthera.2015.05.005. Epub 2015 May 2. Pharmacol Ther. 2015. PMID: 25944528 Review.
Each year, about 5-6 cases out of 100,000 people are diagnosed with primary malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma multiforme (GBM) accounts for more than half of MG cases. ...Lately, efforts have been made to investigate tumor …
Each year, about 5-6 cases out of 100,000 people are diagnosed with primary malignant brain tumors, of which about 80% are malignant …
CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.
Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, Bhute VJ, Torregrosa-Allen S, Elzey BD, Won YY, Deng Q, Lian XL, Wang X, Eniola-Adefeso O, Bao X. Chang Y, et al. Nat Commun. 2023 Apr 20;14(1):2266. doi: 10.1038/s41467-023-37872-4. Nat Commun. 2023. PMID: 37080958 Free PMC article.
While efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and chemotherapeutics, have been developed to treat various cancers, their effectiveness in GBM treatment has been hindered largely by the blood-brain barrier and blood-brain-tu …
While efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and chemotherapeutics, have been developed to treat …
Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma.
Ye Z, Ai X, Yang K, Yang Z, Fei F, Liao X, Qiu Z, Gimple RC, Yuan H, Huang H, Gong Y, Xiao C, Yue J, Huang L, Saulnier O, Wang W, Zhang P, Dai L, Wang X, Wang X, Ahn YH, You C, Xu J, Wan X, Taylor MD, Zhao L, Rich JN, Zhou S. Ye Z, et al. Cancer Discov. 2023 Apr 3;13(4):974-1001. doi: 10.1158/2159-8290.CD-22-0455. Cancer Discov. 2023. PMID: 36649564 Free PMC article.
Glioblastoma (GBM) constitutes the most lethal primary brain tumor for which immunotherapy has provided limited benefit. The unique brain immune landscape is reflected in a complex tumor immune microenvironment (TIME) in GBM. ...
Glioblastoma (GBM) constitutes the most lethal primary brain tumor for which immunotherapy has provided limited benefit. The unique …
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Aldoghachi AF, Aldoghachi AF, Breyne K, Ling KH, Cheah PS. Aldoghachi AF, et al. Neuroscience. 2022 May 21;491:240-270. doi: 10.1016/j.neuroscience.2022.03.030. Epub 2022 Apr 6. Neuroscience. 2022. PMID: 35395355 Review.
Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest malignant types of primary astrocytoma with a poor prognosis. At present, the standard of care includes surgical tumor resection, followed by radiation therapy concomitant with chemothe …
Glioblastoma multiforme (GBM) is one of the most common, most formidable, and deadliest malignant types of primary astrocytoma with a …
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK, Engelhard HH, Lakka SS. Ahir BK, et al. Mol Neurobiol. 2020 May;57(5):2461-2478. doi: 10.1007/s12035-020-01892-8. Epub 2020 Mar 9. Mol Neurobiol. 2020. PMID: 32152825 Free PMC article. Review.
Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clinical research on the potential of exploiting angiogenic pathways as a strategy in the treatment of GBM patients....
Here, in this review, we highlight and summarize the various molecular mediators that regulate GBM angiogenesis with focus on recent clin …
Tumor Treating Fields in the Management of Patients with Malignant Gliomas.
Ghiaseddin AP, Shin D, Melnick K, Tran DD. Ghiaseddin AP, et al. Curr Treat Options Oncol. 2020 Jul 30;21(9):76. doi: 10.1007/s11864-020-00773-5. Curr Treat Options Oncol. 2020. PMID: 32734509 Free PMC article. Review.
Tumor treating fields (TTFields) have emerged as a novel, locoregional, antineoplastic treatment modality with favorable efficacy and safety being demonstrated in the most aggressive type of malignant gliomas, glioblastoma (GBM). In 2 large randomized, controlled phase 3 t …
Tumor treating fields (TTFields) have emerged as a novel, locoregional, antineoplastic treatment modality with favorable efficacy and safety …
891 results